CA2902721C - Compounds and uses thereof for the modulation of hemoglobin - Google Patents
Compounds and uses thereof for the modulation of hemoglobin Download PDFInfo
- Publication number
- CA2902721C CA2902721C CA2902721A CA2902721A CA2902721C CA 2902721 C CA2902721 C CA 2902721C CA 2902721 A CA2902721 A CA 2902721A CA 2902721 A CA2902721 A CA 2902721A CA 2902721 C CA2902721 C CA 2902721C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- compound
- ring
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/815,776 | 2013-03-15 | ||
| US13/815,776 US9458139B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
| US201361905802P | 2013-11-18 | 2013-11-18 | |
| US61/905,802 | 2013-11-18 | ||
| PCT/US2014/022846 WO2014150289A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2902721A1 CA2902721A1 (en) | 2014-09-25 |
| CA2902721C true CA2902721C (en) | 2021-09-14 |
Family
ID=51580734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2902721A Active CA2902721C (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2970315B1 (enExample) |
| JP (2) | JP6401772B2 (enExample) |
| KR (1) | KR20150132147A (enExample) |
| CN (1) | CN105209469A (enExample) |
| AP (1) | AP2015008720A0 (enExample) |
| AU (1) | AU2014237361A1 (enExample) |
| BR (1) | BR112015021980A2 (enExample) |
| CA (1) | CA2902721C (enExample) |
| EA (1) | EA201591427A1 (enExample) |
| ES (1) | ES2909634T3 (enExample) |
| IL (1) | IL240845A0 (enExample) |
| MX (1) | MX388013B (enExample) |
| PE (1) | PE20151907A1 (enExample) |
| SG (1) | SG11201507351PA (enExample) |
| TW (1) | TW201518286A (enExample) |
| UY (1) | UY35425A (enExample) |
| WO (1) | WO2014150289A1 (enExample) |
| ZA (1) | ZA201506390B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| DK3738434T3 (da) | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T2 (sl) | 2014-02-07 | 2024-10-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913999PA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| US10787430B2 (en) | 2016-06-17 | 2020-09-29 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| JP7509772B2 (ja) * | 2018-11-19 | 2024-07-02 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンのモジュレーター |
| US11014908B2 (en) | 2018-11-29 | 2021-05-25 | Pfizer Inc. | Chemical compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR76950B (enExample) * | 1980-12-18 | 1984-09-04 | Wellcome Found | |
| FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU668818B2 (en) * | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
| EP0923580A1 (en) * | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
| US6184228B1 (en) * | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
| AUPQ105499A0 (en) * | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| EP1567490B1 (en) | 2002-12-04 | 2011-10-05 | Virginia Commonwealth University | Anti-sickling agents |
| NZ548049A (en) * | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US20120122928A1 (en) * | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| DK3738434T3 (da) * | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| BR112015021982B1 (pt) * | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
-
2014
- 2014-03-10 AU AU2014237361A patent/AU2014237361A1/en not_active Abandoned
- 2014-03-10 AP AP2015008720A patent/AP2015008720A0/xx unknown
- 2014-03-10 EA EA201591427A patent/EA201591427A1/ru unknown
- 2014-03-10 EP EP14768414.6A patent/EP2970315B1/en active Active
- 2014-03-10 ES ES14768414T patent/ES2909634T3/es active Active
- 2014-03-10 KR KR1020157024775A patent/KR20150132147A/ko not_active Withdrawn
- 2014-03-10 SG SG11201507351PA patent/SG11201507351PA/en unknown
- 2014-03-10 MX MX2015011509A patent/MX388013B/es unknown
- 2014-03-10 WO PCT/US2014/022846 patent/WO2014150289A1/en not_active Ceased
- 2014-03-10 PE PE2015001920A patent/PE20151907A1/es not_active Application Discontinuation
- 2014-03-10 JP JP2016501086A patent/JP6401772B2/ja active Active
- 2014-03-10 CA CA2902721A patent/CA2902721C/en active Active
- 2014-03-10 CN CN201480013378.3A patent/CN105209469A/zh active Pending
- 2014-03-10 BR BR112015021980A patent/BR112015021980A2/pt not_active IP Right Cessation
- 2014-03-13 UY UY35425A patent/UY35425A/es not_active Application Discontinuation
- 2014-03-13 TW TW103108889A patent/TW201518286A/zh unknown
-
2015
- 2015-08-26 IL IL240845A patent/IL240845A0/en unknown
- 2015-09-01 ZA ZA2015/06390A patent/ZA201506390B/en unknown
-
2018
- 2018-09-07 JP JP2018167981A patent/JP2018188481A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512824A (ja) | 2016-05-09 |
| MX388013B (es) | 2025-03-19 |
| EA201591427A1 (ru) | 2016-01-29 |
| KR20150132147A (ko) | 2015-11-25 |
| SG11201507351PA (en) | 2015-10-29 |
| JP2018188481A (ja) | 2018-11-29 |
| EP2970315A4 (en) | 2016-08-17 |
| EP2970315A1 (en) | 2016-01-20 |
| MX2015011509A (es) | 2016-05-31 |
| AP2015008720A0 (en) | 2015-09-30 |
| BR112015021980A2 (pt) | 2017-07-18 |
| ZA201506390B (en) | 2017-03-29 |
| WO2014150289A1 (en) | 2014-09-25 |
| TW201518286A (zh) | 2015-05-16 |
| EP2970315B1 (en) | 2021-09-15 |
| UY35425A (es) | 2014-10-31 |
| JP6401772B2 (ja) | 2018-10-10 |
| IL240845A0 (en) | 2015-10-29 |
| AU2014237361A1 (en) | 2015-09-17 |
| ES2909634T3 (es) | 2022-05-09 |
| CA2902721A1 (en) | 2014-09-25 |
| PE20151907A1 (es) | 2016-01-20 |
| CN105209469A (zh) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2902721A1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| AU2014237340C1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| US10100040B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| US10858317B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| CA2902711C (en) | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin | |
| US10450269B1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| CA2903022A1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| OA17478A (en) | Compounds and uses thereof for the modulation of hemoglobin. | |
| OA17480A (en) | Compounds and uses thereof for the modulation of hemoglobin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190228 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251006 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260423 |